2017
Chapter 10 Sur1–Trpm4-Promising Target for Brain Edema Treatment in Brain Edema From Molecular Mechanisms to Clinical Practice
Urday S, Sheth K, Simard J. Chapter 10 Sur1–Trpm4-Promising Target for Brain Edema Treatment in Brain Edema From Molecular Mechanisms to Clinical Practice. 2017, 183-198. DOI: 10.1016/b978-0-12-803196-4.00010-2.Peer-Reviewed Original ResearchSUR1-TRPM4Brain edemaEdema formationDefinitive phase III studyBrain edema treatmentNeurocritical care conditionsPhase III studyAcute neurological injuryExtravasation of bloodType of edemaMicrovascular failureIII studySignificant morbidityNeurological functionNeurological injuryEdema treatmentSafe medicationSelective blockadeLesion volumeClinical studiesPetechial hemorrhagesCare conditionsEdemaClinical practiceSulfonylurea receptor
2013
Pilot Study of Intravenous Glyburide in Patients With a Large Ischemic Stroke
Sheth KN, Kimberly WT, Elm JJ, Kent TA, Mandava P, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM, Albers GW, Jacobson S, Simard JM, Stern BJ. Pilot Study of Intravenous Glyburide in Patients With a Large Ischemic Stroke. Stroke 2013, 45: 281-283. PMID: 24193798, PMCID: PMC4235339, DOI: 10.1161/strokeaha.113.003352.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlood GlucoseBrain EdemaBrain IschemiaComorbidityFemaleFibrinolytic AgentsGlyburideHumansHypoglycemiaHypoglycemic AgentsInjections, IntravenousMagnetic Resonance ImagingMaleMiddle AgedPatient SafetyPilot ProjectsProspective StudiesStrokeTissue Plasminogen ActivatorTreatment OutcomeWhite PeopleYoung AdultConceptsIschemic strokeLesion volumeIntravenous recombinant tissue-type plasminogen activatorRecombinant tissue-type plasminogen activatorIpsilateral hemisphere volumeLarge ischemic strokeSerious adverse eventsAcute ischemic strokeRetrospective clinical dataFeasibility of recruitingTissue-type plasminogen activatorIntravenous glyburideSevere strokeSymptomatic hypoglycemiaAdverse eventsFocal ischemiaMean ageClinical trialsHemisphere volumeClinical dataDose reductionAge 18PatientsSulfonylurea receptorPlasminogen activator